COMP <GO>
ARQT vs LQDA // FREE CASH FLOW YIELD
Arcutis Biotherapeutics Inc. (NASDAQ) VS. Liquidia Corporation (NASDAQ) • 15-METRIC TALLY: ARQT 8
— LQDA 3
▲ FREE CASH FLOW YIELD LEADER: ARQT
LAST: $32.07 (+0.31%) • MKT CAP: $4.03B
fcf-yield
-0.16%
LAST: $45.06 (+0.16%) • MKT CAP: $4.03B
fcf-yield
-0.99%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARQT VS. LQDA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARQT | LQDA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 90.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -3.00% | -12.60% | +9.60 | ARQT | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -0.16% | -0.99% | +0.83 | ARQT | /fcf-yield <GO> |
| Operating Margin | -3.30% | -32.50% | +29.20 | ARQT | /operating-margins <GO> |
| Net Profit Margin | -4.30% | -43.50% | +39.20 | ARQT | /net-margins <GO> |
| Revenue Growth (YoY) | 91.30% | 180.00% | -88.70 | LQDA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.78 | 6.33 | +1.45 | ARQT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 5/9 | +1.00 | ARQT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.0 | 52.5 | +13.50 | ARQT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.90 | +0.10 | ARQT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 21.0x | +3.00 | LQDA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.03B | $4.03B | -$2.3M | LQDA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARQT REV | LQDA REV | ARQT GROSS % | LQDA GROSS % | ARQT FCF | LQDA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $376.1M | $158.3M | 90.2% | — | -$6.3M | -$40.0M |
| FY 2024 | $196.5M | $14.0M | 90.3% | 58.0% | -$112.3M | -$98.4M |
| FY 2023 | $59.6M | $17.5M | — | — | -$249.7M | -$42.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARQT // BETA 1.00
LQDA // BETA 0.90